Supplementary Table 7. Association of *HSD17B13* rs6834314 genotypes with clinical outcomes by Cox regression analysis

Variable	Univariate analysis HR (95% CI)	*P*-value	Multivariate analysis HR (95% CI)	*P*-value
At least one clinical outcome				
A/A (reference)	–	–	–	–
A/G	1.80 (0.86–3.78)	0.122	1.60 (0.75–3.39)	0.222
G/G	1.79 (0.58–5.50)	0.310	1.09 (0.31–3.89)	0.893
Age	1.03 (0.99–1.06)	0.152	–	–
Gender	0.86 (0.43–1.71)	0.659	–	–
Advanced fibrosis	2.18 (1.03–4.63)	0.042	1.66 (0.76–3.65)	0.205
Serum GGT	1.002 (1.000–1.003)	0.006	1.001 (1.000–1.003)	0.036
Diabetes mellitus	3.94 (1.38–11.25)	0.010	2.58 (0.84–7.93)	0.098
Hypertension	2.74 (0.96–7.83)	0.059	1.87 (0.62–5.60)	0.264
Dyslipidaemia	0.77 (0.24–2.55)	0.674	–	–
BMI	1.01 (0.94–1.08)	0.848	–	–
CVS outcome				
A/A (reference)	–	–	–	–
A/G	1.53 (0.64–3.68)	0.342	1.99 (0.80–4.92)	0.138
G/G	1.11 (0.24–5.09)	0.892	0.82 (0.18–3.84)	0.800
Age	1.01 (0.97–1.05)	0.606	–	–
Gender	1.23 (0.53–2.85)	0.629	–	–
Smoker	1.84 (0.54–6.25)	0.330	–	–
Serum TC	0.92 (0.63–1.34)	0.646	–	–
Serum TG	1.14 (0.79–1.65)	0.484	–	–
Serum HDL-C	0.11 (0.02–0.70)	0.019	0.10 (0.01–0.64)	0.015
Serum LDL-C	0.91 (0.59–1.42)	0.683	–	–
Systolic BP	1.04 (1.01–1.07)	0.020	1.04 (1.01–1.07)	0.022
Diastolic BP	0.97 (0.93–1.01)	0.121	–	–
Diabetes mellitus	2.46 (0.83–7.27)	0.100	2.47 (0.82–7.48)	0.109
Hypertension	2.48 (0.73–8.41)	0.143	–	–
Advanced fibrosis	1.65 (0.64–4.21)	0.299	–	–
Serum GGT	1.00 (0.99–1.00)	0.385	–	–
BMI	1.02 (0.94–1.11)	0.624	–	–
Extrahepatic malignancy				
A/A (reference)	–	–	–	–
A/G	4.40 (0.46–42.33)	0.199	4.43 (0.45–44.09)	0.204
G/G	5.86 (0.36–94.29)	0.212	1.31 (0.04–38.84)	0.876
Age	1.07 (0.97–1.19)	0.187	1.07 (0.96–1.19)	0.248
Gender	0.24 (0.03–2.14)	0.200	–	–
Advanced fibrosis	0.04 (0.00–444.77)	0.487	–	–
Serum GGT	1.003 (1.001–1.005)	0.002	1.003 (1.001–1.006)	0.018
Diabetes mellitus	1.97 (0.22–17.62)	0.545	–	–

Supplementary Table 7. Continued

Variable	Univariate analysis	*P*-value	Multivariate analysis	*P*-value
	HR (95% CI)		HR (95% CI)	
Hypertension	1.48 (0.16–13.25)	0.728	–	–
Dyslipidaemia	Inf (NA)	0.677	–	–
BMI	1.00 (0.83–1.20)	0.981	–	–
All-cause mortality				
A/A (reference)	–	–	–	–
A/G	5.83 (0.65–52.16)	0.115	25.56 (0.51–73.40)	0.104
G/G	4.68 (0.29–75.15)	0.276	0.01 (0.00–1.49)	0.072
Age	1.07 (0.97–1.17)	0.173	1.09 (0.96–1.23)	0.168
Gender	1.02 (0.21–5.08)	0.978	–	–
Advanced fibrosis	0.04 (0.00–215.23)	0.453	–	–
Serum GGT	1.004 (1.002–1.006)	<0.001	1.009 (1.003–1.015)	0.002
Diabetes mellitus	2.40 (0.28–20.58)	0.424	–	–
Hypertension	1.76 (0.21–15.08)	0.607	–	–
Dyslipidaemia	0.40 (0.05–3.41)	0.400	–	–
BMI	1.03 (0.87–1.21)	0.751	–	–

Inf (NA) represented number was too large to be recorded.
HSD17B13, 17β-hydroxysteroid dehydrogenase 13; HR, hazard ratio; CI, confidence interval; GGT, gamma-glutamyl transferase; BMI, body mass index; CVS, cardiovascular; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BP, blood pressure.

 https://doi.org/10.3350/cmh.2020.0162